Dabrafenib (GSK2118436)

Name: Dabrafenib (GSK2118436)
Brand: Selleck Chemicals
SKU: S2807
Rating: 5 (210 reviews)

For research use only.

Catalog No.S2807 Synonyms: GSK2118436A

210 publications

Dabrafenib (GSK2118436) Chemical Structure

CAS No. 1195765-45-7

Dabrafenib (GSK2118436, GSK2118436A) is a mutant BRAFV600 specific inhibitor with IC50 of 0.7 nM in cell-free assays, with 7- and 9-fold less potency against B-Raf(wt) and c-Raf, respectively.

Selleck's Dabrafenib (GSK2118436) has been cited by 210 publications

Nat Biotechnol, 2021, 10.1038/s41587-021-00837-3

PubMed: 33619394 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Nature, 2019, 575(7781):203-209

PubMed: 31666698 ( click the link to review the publication )

Nat Med, 2018, 24(2):203-212

PubMed: 29334371 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Cancer Discov, 2018, 8(4):417-427

PubMed: 29431697 ( click the link to review the publication )

Nature, 2017, 550(7674):133-136

PubMed: 28953887 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Science, 2016, 352(6282):189-96

PubMed: 27124452 ( click the link to review the publication )

Nat Med, 2016, 22(9):1056-61

PubMed: 27500726 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):485-498

PubMed: 27523909 ( click the link to review the publication )

Cancer Discov, 2015, 5(4):358-67

PubMed: 25673644 ( click the link to review the publication )

Cancer Discov, 2014, 4(1):69-79

PubMed: 24265152 ( click the link to review the publication )

Sci Adv, 2021, 7(24)eabg0390

PubMed: 34108213 ( click the link to review the publication )

Nat Commun, 2021, 12(1):1747

PubMed: 33741929 ( click the link to review the publication )

Nucleic Acids Res, 2021, 49(8):4421-4440

PubMed: 33849069 ( click the link to review the publication )

Clin Cancer Res, 2021, 10.1158/1078-0432.CCR-21-2660

PubMed: 34433654 ( click the link to review the publication )

Cancer Res, 2021, 81(20):5230-5241

PubMed: 34462276 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):107

PubMed: 34419074 ( click the link to review the publication )

Oncogene, 2021, 10.1038/s41388-020-01628-x

PubMed: 33500549 ( click the link to review the publication )

Sci Signal, 2021, 14(682)eabc1648

PubMed: 33975980 ( click the link to review the publication )

Cancers (Basel), 2021, 13(9)2175

PubMed: 33946525 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3487

PubMed: 34298699 ( click the link to review the publication )

Cancers (Basel), 2021, 13(14)3635

PubMed: 34298852 ( click the link to review the publication )
Pigment Cell Melanoma Res, 2021, 10.1111/pcmr.13014

PubMed: 34482636 ( click the link to review the publication )

Cell Death Dis, 2021, 12(7):699

PubMed: 34262020 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):85

PubMed: 33446653 ( click the link to review the publication )

Cell Death Discov, 2021, 7(1):127

PubMed: 34059622 ( click the link to review the publication )

Cell Death Dis, 2021, 12(9):816

PubMed: 34462421 ( click the link to review the publication )

J Clin Endocrinol Metab, 2021, dgab020

PubMed: 33524147 ( click the link to review the publication )

Endocr Relat Cancer, 2021, 28(5):311-324

PubMed: 33769310 ( click the link to review the publication )

Clin Sci (Lond), 2021, 135(14):1631-1647

PubMed: 34296750 ( click the link to review the publication )

Neoplasia, 2021, 23(5):539-550

PubMed: 33971465 ( click the link to review the publication )

Biomolecules, 2021, 11(2)153

PubMed: 33503908 ( click the link to review the publication )

Gynecol Oncol, 2021, S0090-8258(21)00648-X

PubMed: 34391578 ( click the link to review the publication )

Front Oncol, 2021, 11:656453

PubMed: 33898322 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(4)1801

PubMed: 33670365 ( click the link to review the publication )

J Proteome Res, 2021, 10.1021/acs.jproteome.1c00331

PubMed: 34343000 ( click the link to review the publication )

Mol Imaging Biol, 2021, 10.1007/s11307-021-01615-y

PubMed: 34101107 ( click the link to review the publication )

Molecules, 2021, 26(8)2141

PubMed: 33917810 ( click the link to review the publication )

Eur J Pharmacol, 2021, 906:174214

PubMed: 34116044 ( click the link to review the publication )

Oncol Lett, 2021, 22(5):745

PubMed: 34539849 ( click the link to review the publication )

Biomed Chromatogr, 2021, e5205

PubMed: 34192355 ( click the link to review the publication )

Oncol Rep, 2021, 45(4)14

PubMed: 33649790 ( click the link to review the publication )

J Physiol Biochem, 2021, 10.1007/s13105-021-00789-x

PubMed: 33587254 ( click the link to review the publication )

Cell Rep Med, 2021, 2(7):100350

PubMed: 34337566 ( click the link to review the publication )

Cancer Immunol Res, 2021, 10.1158/2326-6066.CIR-20-0905

PubMed: 33653716 ( click the link to review the publication )

Mol Carcinog, 2021, 60(3):201-212

PubMed: 33595872 ( click the link to review the publication )
Sci Adv, 2020, 22;6(21):eaaz8521

PubMed: 32494745 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202004707

PubMed: 32561648 ( click the link to review the publication )

EMBO Rep, 2020, e50163

PubMed: 33369872 ( click the link to review the publication )

Eur J Cancer, 2020, 144:17-30

PubMed: 33316635 ( click the link to review the publication )

Oncogene, 2020, 39(20):4132-4154

PubMed: 32238882 ( click the link to review the publication )

Cancer Lett, 2020, 495:135-144

PubMed: 32979462 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3205

PubMed: 33143299 ( click the link to review the publication )

Cancers (Basel), 2020, 22;12(2) pii: E512

PubMed: 32098410 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2981

PubMed: 33066704 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2020, 10.1111/pcmr.12932

PubMed: 33000894 ( click the link to review the publication )

Cell Death Dis, 2020, 11(11):973

PubMed: 33184267 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):156

PubMed: 32967672 ( click the link to review the publication )

ACS Infect Dis, 2020, acsinfecdis.0c00486

PubMed: 33183004 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Sci Rep, 2020, 8;10(1):7826

PubMed: 32385388 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5557

PubMed: 32221312 ( click the link to review the publication )

J Biol Chem, 2020, 295(8):2407-2420

PubMed: 31929109 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 13

PubMed: 32404982 ( click the link to review the publication )

Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

Pathol Oncol Res, 2020, 10.1007/s12253-020-00834-y

PubMed: 32591993 ( click the link to review the publication )

Anticancer Res, 2020, 40(4):1867-1874

PubMed: 32234874 ( click the link to review the publication )

Br J Cancer, 2020, 122(6):789-800

PubMed: 31932756 ( click the link to review the publication )

Biology (Basel), 2020, 9(8):E218

PubMed: 32785105 ( click the link to review the publication )
ESMO Open, 2020, 5(4):e000707

PubMed: 32817058 ( click the link to review the publication )

Neoplasia, 2020, 22(9):376-389

PubMed: 32629178 ( click the link to review the publication )

Vet Pathol, 2020, 300985820967449

PubMed: 33205710 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3946

PubMed: 32770055 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):387-402

PubMed: 32142667 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(49):31105-31113

PubMed: 33229534 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Acta Neuropathol Commun, 2020, 8(1):139

PubMed: 32811569 ( click the link to review the publication )

Mol Cell, 2019, 76(6):872-884

PubMed: 31606273 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2197

PubMed: 31097693 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5143

PubMed: 31723142 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(21):6429-6442

PubMed: 31439581 ( click the link to review the publication )

Cancer Res, 2019,

PubMed: 31362929 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 29(3):573-588

PubMed: 31618628 ( click the link to review the publication )

Cell Death Differ, 2019, 10.1038/s41418-019-0298-5

PubMed: 30742091 ( click the link to review the publication )

Eur J Cancer, 2019, 109:137-153

PubMed: 30721788 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):272

PubMed: 31227006 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):56

PubMed: 30728057 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31547367 ( click the link to review the publication )

Cancers (Basel), 2019, 11(9)

PubMed: 31533235 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12824

PubMed: 31518489 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )
Acta Neuropathol Commun, 2019, 7(1):128

PubMed: 31391125 ( click the link to review the publication )

Acta Neuropathol Commun, 2019, 7(1):119

PubMed: 31345255 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

Mol Pharm, 2019, 16(9):3904-3915

PubMed: 31318566 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113616

PubMed: 31445021 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1225

PubMed: 30718660 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:223

PubMed: 31467489 ( click the link to review the publication )

Surgery, 2019, 10.1016/j.surg.2019.04.076

PubMed: 31585718 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Metabolites, 2019, 9(11)

PubMed: 31744229 ( click the link to review the publication )

Chembiochem, 2019, 10.1002/cbic.201900266

PubMed: 31152574 ( click the link to review the publication )

PLoS One, 2019, 14(6):e0217399

PubMed: 31158244 ( click the link to review the publication )

Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520

PubMed: 31618797 ( click the link to review the publication )

Reprod Domest Anim, 2019, 54(5):741-749

PubMed: 30785650 ( click the link to review the publication )

Target Oncol, 2019, 14(5):619-626

PubMed: 31502118 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav8463

PubMed: 31453322 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

Ann Biomed Eng, 2019, 10.1007/s10439-019-02269-2

PubMed: 31020445 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10865

PubMed: 31350469 ( click the link to review the publication )

Exp Gerontol, 2019, 126:110691

PubMed: 31421186 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31783660 ( click the link to review the publication )

Transl Oncol, 2019, 13(2):275-286

PubMed: 31874374 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )
Nat Biomed Eng, 2018, 2(4):239-253

PubMed: 30936439 ( click the link to review the publication )

Mol Cell, 2018, 69(6):923-937

PubMed: 29547721 ( click the link to review the publication )

Mol Cell, 2018, 70(5):920-935

PubMed: 29883609 ( click the link to review the publication )

Nat Protoc, 2018, 13(12):2827-2843

PubMed: 30382243 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3440

PubMed: 30143629 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2500

PubMed: 29950559 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1466

PubMed: 29654229 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(5):1090-1102

PubMed: 29196297 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(14):3377-3385

PubMed: 29650750 ( click the link to review the publication )

Cancer research, 2018, 78(2):542-557

PubMed: 29180473 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Breast Cancer Res, 2018, 20(1):9

PubMed: 29382358 ( click the link to review the publication )

Cell Chem Biol, 2018, 25(2):175-184

PubMed: 29249695 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(1):84-95

PubMed: 29133617 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Mol Oncol, 2018, 12(1):74-88

PubMed: 29112787 ( click the link to review the publication )

Neoplasia, 2018, 20(5):467-477

PubMed: 29605720 ( click the link to review the publication )

Hum Mol Genet, 2018, 27(22):3974-3985

PubMed: 30137437 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):67

PubMed: 30190455 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9991

PubMed: 29968772 ( click the link to review the publication )

Front Pharmacol, 2018, 9:856

PubMed: 30154717 ( click the link to review the publication )

ACS Med Chem Lett, 2018, 9(12):1199-1204

PubMed: 30613326 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):355-361

PubMed: 29534162 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )
Oncotarget, 2018, 9(92):36503-36514

PubMed: 30559933 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):325

PubMed: 29487283 ( click the link to review the publication )

Oncotarget, 2018, 9(17):13324-13336

PubMed: 29568360 ( click the link to review the publication )

Small GTPases, 2018, 10.1080/21541248.2018.1446697

PubMed: 29634387 ( click the link to review the publication )

Sci Rep, 2018, 8(1):10724

PubMed: 30013176 ( click the link to review the publication )

NPJ Syst Biol Appl, 2018, 4:39

PubMed: 30416750 ( click the link to review the publication )

Oncoimmunology, 2018, 8(1):e1512456

PubMed: 30546949 ( click the link to review the publication )

Cell Syst, 2018, 7(2):161-179

PubMed: 30007540 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28294-28308

PubMed: 29983861 ( click the link to review the publication )

Neural Regen Res, 2018, 13(2):252-256

PubMed: 29557374 ( click the link to review the publication )

Nat Commun, 2017, 8:15623

PubMed: 28585535 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Cancer Res, 2017, 77(17):4684-4696

PubMed: 28652244 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(19):3631-3645

PubMed: 28551825 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Transl Lung Cancer Res, 2017, 6(5):600-610

PubMed: 29114475 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15523

PubMed: 29138474 ( click the link to review the publication )

Anal Bioanal Chem, 2017, 409(15):3749-3756

PubMed: 28429064 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2741-2751

PubMed: 29048639 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68208-68220

PubMed: 28978109 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(11 Pt B):2980-2992

PubMed: 28408301 ( click the link to review the publication )
Cell Death Differ, 2017, 24(1):83-97

PubMed: 27834956 ( click the link to review the publication )

Genome Res, 2017, 27(4):613-625

PubMed: 28179366 ( click the link to review the publication )

Oncogene, 2017, 36(27):3842-3851

PubMed: 28263969 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28350298 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(29):E5930-E5939

PubMed: 28684402 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(10)

PubMed: 29064427 ( click the link to review the publication )

Oncotarget, 2017, 8(52):90262-90277

PubMed: 29163826 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Blood Adv, 2017, 30;1(24):2147-2160

PubMed: 29296862 ( click the link to review the publication )

Nat Commun, 2016, 7:10274

PubMed: 26817517 ( click the link to review the publication )

Autophagy, 2016, 12(10):1776-1790

PubMed: 27464255 ( click the link to review the publication )

Leukemia, 2016, 30(4):937-46

PubMed: 26582644 ( click the link to review the publication )

Mol Cancer Ther, 2016, 10.1158/1535-7163.MCT-15-0375

PubMed: 27196768 ( click the link to review the publication )

J Biol Chem, 2016, 291(34):17804-15

PubMed: 27226552 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(7):778-84

PubMed: 26810603 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0152104

PubMed: 27015094 ( click the link to review the publication )

Oncotarget, 2016, 8(35):58021-58036

PubMed: 28938534 ( click the link to review the publication )

Oncotarget, 2016, 7(21):30453-60

PubMed: 27028853 ( click the link to review the publication )

Sci Rep, 2016, 6:23713

PubMed: 27025703 ( click the link to review the publication )

Elife, 2016, 5

PubMed: 27557444 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75839-75853

PubMed: 27713119 ( click the link to review the publication )

Oncotarget, 2016, 7(12):15065-92

PubMed: 26918341 ( click the link to review the publication )

Cell Res, 2015, 10.1038/cr.2015.56

PubMed: 25952668 ( click the link to review the publication )

Mol Ther, 2015, 23(5):931-942

PubMed: 25619724 ( click the link to review the publication )
J Invest Dermatol, 2015, 135(8):2021-2030

PubMed: 25748555 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

J Immunother, 2015, 38(1):12-23

PubMed: 25415284 ( click the link to review the publication )

Eur J Pharmacol, 2015, 762:283-92

PubMed: 26048310 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Cancer Res, 2015, 75(1):216-29

PubMed: 25381152 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(12):1934-7

PubMed: 26443648 ( click the link to review the publication )

Oncotarget, 2015, 6(38):40535-56

PubMed: 26497853 ( click the link to review the publication )

Cancer Immunol Res, 2015, 3(6):602-9

PubMed: 25795007 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2700-11

PubMed: 26351322 ( click the link to review the publication )

J Clin Invest, 2014, 124(3):1406-17

PubMed: 24569374 ( click the link to review the publication )

J Clin Invest, 2014, 124(11):5074-84

PubMed: 25329694 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1278

PubMed: 24901049 ( click the link to review the publication )

Transl Res, 2014, 164(5):411-23

PubMed: 25016932 ( click the link to review the publication )

The University of Texas, 2014, Lizee S

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description

Targets

B-Raf (V600E) ^[3] (Cell-free assay)	B-Raf ^[3] (Cell-free assay)	C-Raf ^[3] (Cell-free assay)
0.7 nM	5.2 nM	6.3 nM

In vitro

Dabrafenib is selective for Raf kinase, with 400 fold selectivity towards B-Raf over 91% of the other kinases tested. Dabrafenib inhibits B-Raf^V600E kinase, leading to decreased ERK phosphorylation and inhibition of cell proliferationby an initial arrest in the G1 phase of the cell cycle in cancer cells that specifically encode the mutation for B-Raf^V600E. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
	NYfxeVB1U2mwYYPlJGF{e2G7				M3L6VWlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDIbZMhfGGpZ3XkJGIuWmGoIG[2NFBGKG23dHHueEBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgbY5{\WO2IHPlcIx{KGOxLXX4dJJme3OrbnegR2REOzdiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[mmxdHnufYxifGWmLV3FT{Bxem:2ZXnuJJBpd3OyaH;yfYxifGmxbjDifUBCdHCqYWPjdoVmdiCjc4PhfUB4cXSqIFnDOVAhd2ZiMD6wNFA4KM7:TR?=	M{PhRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc{Lz5{NEmwNFY4OzxxYU6=
SK-MEL-28	NEnDNZlMcW6jc3WgRZN{[Xl?		MWOxJIg>		NUDVVppXUW6qaXLpeIlwdiCxZjDCMXJi\iCYNkCwSUBufXSjboSgbY4hcHWvYX6gV2suVUWOLUK4JINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKEWUSzDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB2IN88US=>	NVHSRpk6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA3PzNpPkK0PVAxPjd\|PD;hQi=>
HepG2	M1PpeWtqdmG\|ZTDBd5NigQ>?				NF2yeJVKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdDDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDFVmsheGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkCwOEDPxE1?	NEDpdo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4Oyd-MkS5NFA3PzN:L3G+
COLO205	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTZc49KdmirYnn0bY9vKG:oIHj1cYFvKEORTF:yNFUh[2WubDDwdo9tcW[ncnH0bY9vKHerdHigTWM2OCCxZjCwMlAxPyEQvF2=	MkLCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC2O\|MoRjJ2OUCwOlc{RC:jPh?=
HepG2	MmK0SpVv[3Srb36gRZN{[Xl?		NIPCXpE1PSCvaX6=	MnrCSG1UVw>?	Mn7BTY5pcWKrdHnvckBw\iCDbHu1JIlvKFSJRj3i[ZRiNXO2aX31cIF1\WRiaIXtZY4hUGWyR{KgZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hW22jZEKgdIhwe3Cqb4L5cIF1cW:wIITy[YF1\WRiZn;yJFQ2KG2rboOgdJJqd3JidH:gWGdHNWKndHGgd5RqdXWuYYTpc44hdWWjc4Xy[YQh[W[2ZYKgOlAhdWmwczDifUBw\Hm\|c3X5JIJtd3Ric3Phco5meiCjbnHsfZNqeyC5aYToJGlEPTBib3[gN{44KM7:TR?=	M3LPdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwOlc{Lz5{NEmwNFY4OzxxYU6=
HFF	NHvPW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PYdVExKM7:TR?=	MkXFO\|IhcA>?	MmO4SG1UVw>?	MUTJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhcHWvYX6gTGZHKGOnbHzzJIhiemKxcnnu[{B4cWymIIT5dIUhSi2UYX[ge4l1cCCLQ{WwJI9nKDNizszN	NHX3V3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmwNFY4Oyd-MkS5NFA3PzN:L3G+
SK-MEL-28	Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\LNVAh\|ryP	NIGwcYg4OiCq	NX\BOItLTE2VTx?=	MkTnTY5pcWKrdHnvckBw\iCELWLh[kBXPjByRTDteZRidnRvZILpeoVvKFONLV3FUE0zQCClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvODR\|IN88US=>	M1H3SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A375P-F11	MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV6xNEDPxE1?	M2[5Z\|czKGh?	M1PVZmROW09?	NFPNXHZKdmirYnn0bY9vKG:oIFKtVoFnKFZ4MEDFJI12fGGwdD3kdol3\W5iQUO3OXAuTjFzIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yN{Gg{txO	NViwVGt3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
MALME-3M	Mn\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYS2WIhwOTBizszN	NGnDNZM4OiCq	NWTybXRnTE2VTx?=	NG\LfG5KSzVyPUGgcm0>	NFnj[Wc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
UACC-62	NWPoZlV[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3[4clExKM7:TR?=	MYi3NkBp	MXfEUXNQ	NWTBdlZ4UUN3ME2xJI5O	M33ueVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
C32TG	MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUmxNEDPxE1?	NUfCfmFZPzJiaB?=	MoO2SG1UVw>?	NGe1W3pKSzVyPUGgcm0>	NHTmRZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-MEL-1	Mn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PSblExKM7:TR?=	MlLvO\|IhcA>?	NFjKZnRFVVOR	NY\UPWsxUUN3ME2yJI5O	NG\nTpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
M14	NWn5d\|gyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfXNVAh\|ryP	NH2wWWw4OiCq	M{TsbGROW09?	M4fNdWlEPTB;MjDuUS=>	NILuNGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SK-MEL-28	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVWxNEDPxE1?	M1\jd\|czKGh?	M1rzcmROW09?	MVrJR\|UxRTNibl2=	NVnIN3c3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
A375	NV72NHFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zz[lExKM7:TR?=	MUC3NkBp	NUDMT21kTE2VTx?=	MVXJR\|UxRTRibl2=	NVK4S\|huRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
DU-4475	MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWmxNEDPxE1?	Mn\SO\|IhcA>?	MV7EUXNQ	MWnJR\|UxRTVibl2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
UACC-257	NX\WeZVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTMTId{OTBizszN	MXO3NkBp	MYnEUXNQ	MkftTWM2OD14IH7N	NGHtU\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Colo 205	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX6xNEDPxE1?	M2rqVFczKGh?	MV\EUXNQ	MVnJR\|UxRTdibl2=	NXf2fHNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SK-MEL-3	MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fGWlExKM7:TR?=	NVPX[ZYzPzJiaB?=	Mn;xSG1UVw>?	NELnNZRKSzVyPUegcm0>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SH-4	M3HaTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzSN5AyOCEQvF2=	NF\5XGI4OiCq	NGDjN4RFVVOR	NGLIeGNKSzVyPUigcm0>	NVewRYxHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
A101D	NEfabVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHPUFgyOCEQvF2=	MVm3NkBp	MmDQSG1UVw>?	NU\M[GNwUUN3ME25JI5O	NY\jVZJ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
ES-2	MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn2wNVAh\|ryP	M1znelczKGh?	NW\WUo9ZTE2VTx?=	NITBdoZKSzVyPUWzJI5O	NEHDTnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HT-29	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTJUoQyOCEQvF2=	NInHfHE4OiCq	MluxSG1UVw>?	NVHqfZlVUUN3ME22OkBvVQ>?	MmHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW1417	NF;IcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHOwXlkyOCEQvF2=	NX7PSIpPPzJiaB?=	NXTabpc3TE2VTx?=	MlPYTWM2OD1zNUigcm0>	M1PQclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW872	NUXUfoRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jHNlExKM7:TR?=	MUK3NkBp	NF7SbmJFVVOR	M{HTXmlEPTB;M{e3JI5O	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
RKO	NWroVFRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PDPVExKM7:TR?=	MUG3NkBp	NInhe5RFVVOR	MlHJTWM2OD1{LkWyNkDPxE1?	MkXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
A673	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nBc\|ExKM7:TR?=	NYn0dVhoPzJiaB?=	NXXtcXl6TE2VTx?=	M2\FOWlEPTB;MUCg{txO	Ml\nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
GCT	M3nMZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnTN4NyOTBizszN	MVi3NkBp	M{LyO2ROW09?	NITLS4ZKSzVyPUGwJO69VQ>?	M4PmblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
WM-115	NXzOZYt6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLlNVAh\|ryP	NWnpOWpqPzJiaB?=	M4P1U2ROW09?	M1yxZWlEPTB;NTDuUS=>	MljoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
YUMAC	NWjaXYRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXK5eGNlOTBizszN	MVm3NkBp	NULuNHl6TE2VTx?=	NWDMXlZpUUN3ME21JI5O	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
OV-90	M3jhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlThNVAh\|ryP	M3zUSFczKGh?	NF:5SJZFVVOR	NFLsZ5ZKSzVyPUK5JI5O	NYXGSpVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H508	M4TFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITuNo8yOCEQvF2=	NV25U3BJPzJiaB?=	M2TN[WROW09?	M3Tm[mlEPTB;MUCg{txO	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
MDA-MB-231	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1u1UVExKM7:TR?=	MYm3NkBp	MYfEUXNQ	M2DNOGlEPTB;MUCg{txO	MkG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SW756	NFftUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHhe3gyOCEQvF2=	NFvJOXg4OiCq	MnWySG1UVw>?	M1zKeWlEPTB;MUCg{txO	M1ezZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW-837	M1fwNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYe2[YR2OTBizszN	M4POV\|czKGh?	MlXPSG1UVw>?	MXHJR\|UxRTFyIN88US=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
UMUC-3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWWxNEDPxE1?	MnLhO\|IhcA>?	MnTjSG1UVw>?	MkDYTWM2OD1zMDFOwG0>	NY\5[YZERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
LS-174T	MonRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvyRVgyOCEQvF2=	MXe3NkBp	MUfEUXNQ	NUW2RolLUUN3ME2xNEDPxE1?	NEDKWZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A549	NGDPbnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDOWHAyOCEQvF2=	MlnqO\|IhcA>?	M33QSWROW09?	MkHOTWM2OD1zMDFOwG0>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SHP-77	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYixNEDPxE1?	NXLZdGN6PzJiaB?=	M4jOUmROW09?	MWrJR\|UxRTFyIN88US=>	M3\XWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW480	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\rbFIyOCEQvF2=	MXq3NkBp	MVTEUXNQ	M4PL[2lEPTB;MUCg{txO	NY\EPJhlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
DLD-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfq[pg6OTBizszN	M2DqTFczKGh?	NVG0NXZXTE2VTx?=	M{X1RWlEPTB;MUCg{txO	Mmi3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HCT-116	NVjDSpRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXHeGMyOCEQvF2=	M1nFeFczKGh?	MWHEUXNQ	MmrlTWM2OD1zMDFOwG0>	Mk\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H747	NHTMUJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDaNVAh\|ryP	NGPVe484OiCq	M2[5cmROW09?	M1X3eWlEPTB;MUCg{txO	NFS1[nk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
T-84	MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn63NVAh\|ryP	MWC3NkBp	NVjjfGtPTE2VTx?=	MXXJR\|UxRTFyIN88US=>	MoDVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H460	NGTvS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGf2PYkyOCEQvF2=	MlLYO\|IhcA>?	M4PhZWROW09?	Ml;ZTWM2OD1zMDFOwG0>	NIewUXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Calu-6	M4S2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYP1cpZDOTBizszN	NGjzS5E4OiCq	MVzEUXNQ	NVXESoN1UUN3ME2xNEDPxE1?	NXeySmgzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HCC-2998	NHfpPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnv1NVAh\|ryP	NWrWbGdGPzJiaB?=	MlLMSG1UVw>?	MoGzTWM2OD1zMDFOwG0>	M363[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
LS1034	NIntWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVGxNEDPxE1?	NXLHPYZ5PzJiaB?=	MX\EUXNQ	M33uNGlEPTB;MUCg{txO	NFzvOHg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CHP-212	MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVyxNEDPxE1?	MUi3NkBp	MU\EUXNQ	NYHFXHQyUUN3ME2xNEDPxE1?	M4LzTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-N-AS	M2DBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjodpQyOCEQvF2=	MlLLO\|IhcA>?	NGjxc3FFVVOR	MVHJR\|UxRTFyIN88US=>	NY[zXYsxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
BFTC-905	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVe4[nMyOTBizszN	MXG3NkBp	NX7zSXVTTE2VTx?=	MkLnTWM2OD1zMDFOwG0>	NV\VTGtpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HuT78	NGSzeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGDGSHQyOCEQvF2=	NUD4PIN[PzJiaB?=	MlzkSG1UVw>?	MWfJR\|UxRTV{IH7N	MnH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
RPMI-8226	M4LRdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVGxNEDPxE1?	M1HvUFczKGh?	NYDDN\|g5TE2VTx?=	MVzJR\|UxRTJ4MzDuUS=>	NYDGW3ZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
BC-3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2xNEDPxE1?	NXr6UHF{PzJiaB?=	NWrOUGZGTE2VTx?=	M122b2lEPTB;Mke3JI5O	NWLad2hqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
ACHN	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPxNVAh\|ryP	NHjPV\|Q4OiCq	NH62OnpFVVOR	NH7ydFZKSzVyPUK5OEBvVQ>?	MlrXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
JRT3-T35	M{PCT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkL0NVAh\|ryP	MX63NkBp	NH7HNGlFVVOR	NXrEVZJYUUN3ME2yPVUhdk1?	M3juclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-MES-1	Ml;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvHUVRqOTBizszN	M1\qN\|czKGh?	Ml\ISG1UVw>?	NGXNNVNKSzVyPUOyPUBvVQ>?	NXvvR5V2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
CESS	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHv4S2oyOCEQvF2=	MlLMO\|IhcA>?	NXzzWW5STE2VTx?=	NXPPR4tNUUN3ME20PVchdk1?	NX[xeVVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
H4	M4KyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVmxOlA5OTBizszN	MWm3NkBp	MoG5SG1UVw>?	MmjRTWM2OD14MUmgcm0>	NVjrblJMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
BC-1	NH\nNWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fBOlExKM7:TR?=	MUC3NkBp	NXHqW4RDTE2VTx?=	Ml3NTWM2OD15MESgcm0>	MoPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
DB	NXW0N5dbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7xNVAh\|ryP	M1vKSVczKGh?	NYnOPHRxTE2VTx?=	NWHkXpZVUUN3ME24O\|Mhdk1?	MlvSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
RPMI-6666	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlX3NVAh\|ryP	M1vCeVczKGh?	Mn32SG1UVw>?	NWXLVZVOUUN3ME25Nlghdk1?	M{fhNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
MC/CAR	NX;SUVBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV2xNEDPxE1?	NFHYOYY4OiCq	MWPEUXNQ	NH\xfnRKSzVyPUGuNFAzKM7:TR?=	MojhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SNU-1	NYSzRoZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFSzdnUyOCEQvF2=	NX3wR4FqPzJiaB?=	M4nvemROW09?	MoPGTWM2OD1zLkWwNUDPxE1?	NETJTHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CEM/C1	NUiwS2txT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWqxNEDPxE1?	M1XaVlczKGh?	MVLEUXNQ	NY[1S4hwUUN3ME2xMlc4OyEQvF2=	NUPsSYt[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
GDM-1	NFfiU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2LOeVExKM7:TR?=	MWS3NkBp	NYXKb3l3TE2VTx?=	MlrYTWM2OD1zLkm5O{DPxE1?	NGLoXIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HT-1080	M2GycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDUV5lZOTBizszN	MkLDO\|IhcA>?	NF20SXNFVVOR	MmTKTWM2OD1{LkCwOEDPxE1?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HL-60	MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWKxNEDPxE1?	NHfOcpE4OiCq	NWjFdYFQTE2VTx?=	MVLJR\|UxRTJwMUe4JO69VQ>?	M{nBR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
C3A	NIHtWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\PbmY4OTBizszN	MkfhO\|IhcA>?	M3LmNWROW09?	MlP6TWM2OD13LkSxOEDPxE1?	Mmr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MES-SA	NWLz[lFFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrZNVAh\|ryP	M1nORlczKGh?	MYXEUXNQ	MmHBTWM2OD14Lkm4PUDPxE1?	M4jQ[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
22Rv1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHISWl4OTBizszN	MXW3NkBp	NW[3cG5CTE2VTx?=	MoHSTWM2OD1zMDFOwG0>	M4S3NVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
647-V	NFrqb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFf0OFgyOCEQvF2=	MXi3NkBp	NUjrNYlvTE2VTx?=	NX3pPI5CUUN3ME2xNEDPxE1?	NF7hRYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
786-O	NGDRdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV:xNEDPxE1?	M{OwfVczKGh?	M1;udmROW09?	NH[ySWtKSzVyPUGwJO69VQ>?	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
A172	M4C5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\nNVAh\|ryP	MUi3NkBp	MnHkSG1UVw>?	MV7JR\|UxRTFyIN88US=>	NILYNGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
A204	NVHOPGlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4D3[\|ExKM7:TR?=	NXHiNWxWPzJiaB?=	NXrnNVZKTE2VTx?=	M{nETGlEPTB;MUCg{txO	M13WeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A427	M4T0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV36V4x7OTBizszN	M4PCU\|czKGh?	NHLufVhFVVOR	NHLFXXhKSzVyPUGwJO69VQ>?	MmfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
A431	M4rmcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVuxNEDPxE1?	M2rFXlczKGh?	NVTqOnd7TE2VTx?=	NVrYSHpTUUN3ME2xNEDPxE1?	NX;wWmhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
A2780	MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1iyVFExKM7:TR?=	MmLmO\|IhcA>?	MWTEUXNQ	NXLqWmJPUUN3ME2xNEDPxE1?	M2HjTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
ARH-77	Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTXNVAh\|ryP	MVO3NkBp	NF\YOYNFVVOR	NWrxfFhRUUN3ME2xNEDPxE1?	NGL3W\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Be(2)C	M17EWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3a[lMyOCEQvF2=	NYrXTpJ1PzJiaB?=	MkT2SG1UVw>?	Ml35TWM2OD1zMDFOwG0>	NX3HXok1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
BT-20	M2Ptc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnGbohqOTBizszN	NEDtOXk4OiCq	NHvXVllFVVOR	M1;J[GlEPTB;MUCg{txO	NWKwWG5iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
BxPc3	M13ZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DTVVExKM7:TR?=	NHPpPW44OiCq	NW\jXJZJTE2VTx?=	MYXJR\|UxRTFyIN88US=>	NXj4WFQyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
C-4 I	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPNe4gyOTBizszN	MnLFO\|IhcA>?	M4HHVmROW09?	NYrnbIdWUUN3ME2xNEDPxE1?	MoiyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
C33A	M3vmXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\WbmEyOCEQvF2=	M2jNRlczKGh?	M1nWSmROW09?	MVPJR\|UxRTFyIN88US=>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
CAL-27	MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmr4NVAh\|ryP	MlSyO\|IhcA>?	NYrwOVl6TE2VTx?=	MY\JR\|UxRTFyIN88US=>	NVjiVWJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
CAL-62	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3e4U\|ExKM7:TR?=	M1H4UVczKGh?	MWnEUXNQ	MVnJR\|UxRTFyIN88US=>	NHPo[WM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
Calu-3	NHLQfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVyxNEDPxE1?	MWK3NkBp	MknLSG1UVw>?	M1;PbWlEPTB;MUCg{txO	MmD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
CaOV3	M4jvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLKT5MyOCEQvF2=	MW[3NkBp	NH3iNVVFVVOR	M2LyfGlEPTB;MUCg{txO	NXnRUlhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
CGTHW1	MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LzcFExKM7:TR?=	NHLDN3Y4OiCq	NEOxcFlFVVOR	MVvJR\|UxRTFyIN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
CHL-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPDNpUyOCEQvF2=	MYe3NkBp	M4TGUWROW09?	NHXQUZpKSzVyPUGwJO69VQ>?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Colo320DM	NWe0fnptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DBW\|ExKM7:TR?=	MmLUO\|IhcA>?	MWHEUXNQ	NEG5TWFKSzVyPUGwJO69VQ>?	MkXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Colo704	MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjXcHU1OTBizszN	M33ySlczKGh?	M{nuXmROW09?	MUXJR\|UxRTFyIN88US=>	MlLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
COR-L23	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnkNVAh\|ryP	MXe3NkBp	NFH5ZWpFVVOR	MX3JR\|UxRTFyIN88US=>	NIT4bWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
CRO-AP2	M{ThWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUGxNEDPxE1?	NF3zNlU4OiCq	NXLUU4pLTE2VTx?=	NVPnOIpnUUN3ME2xNEDPxE1?	MnjFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Daudi	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjDNVAh\|ryP	MWi3NkBp	NHe4NZRFVVOR	NXGzdWM5UUN3ME2xNEDPxE1?	NXrlSnY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
DOTC 24510	NV3zZm9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\DNVAh\|ryP	MXq3NkBp	MUnEUXNQ	Ml\MTWM2OD1zMDFOwG0>	MlXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
DU-145	NF[wOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzYNXpJOTBizszN	NGLvcYo4OiCq	MVHEUXNQ	Moi4TWM2OD1zMDFOwG0>	Mkj4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
EB-3	MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzBNVAh\|ryP	NEL3NFA4OiCq	NVm1S5h1TE2VTx?=	NWnCZ3o{UUN3ME2xNEDPxE1?	NInqZ4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
EFM-19	NGrqXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PDUFExKM7:TR?=	NU\QcHRxPzJiaB?=	NGjhOG1FVVOR	MUHJR\|UxRTFyIN88US=>	NX7xR2dyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
EKVX	MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3[1NFExKM7:TR?=	MXK3NkBp	MVPEUXNQ	NHnPdIVKSzVyPUGwJO69VQ>?	NUDMeVBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
FaDu	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvUU4UyOCEQvF2=	MmnFO\|IhcA>?	NH6zbHZFVVOR	NX3ySI9{UUN3ME2xNEDPxE1?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
G401	Mme3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\uU\|ExKM7:TR?=	MWm3NkBp	NY\1SoRITE2VTx?=	MonaTWM2OD1zMDFOwG0>	NX7UTFRpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
HCC-70	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTiNVAh\|ryP	MUW3NkBp	MU\EUXNQ	NWrCb\|dnUUN3ME2xNEDPxE1?	MnHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HCC-1954	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVmxNEDPxE1?	MYq3NkBp	NE\J[G1FVVOR	MVfJR\|UxRTFyIN88US=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Hela	NFTx[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPMNVAh\|ryP	NXzBe4dRPzJiaB?=	MkXtSG1UVw>?	NW\NNYpCUUN3ME2xNEDPxE1?	NXjrWld1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Hep3B	NI\vOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoC0NVAh\|ryP	NWXuNZpTPzJiaB?=	MXvEUXNQ	M4jDcGlEPTB;MUCg{txO	M{P5dVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HMCB	MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVH5b2J6OTBizszN	M1vk[\|czKGh?	NFK1[mJFVVOR	NXfZd5k3UUN3ME2xNEDPxE1?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HN5	M1;BUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHJ[28yOCEQvF2=	MXK3NkBp	MoTSSG1UVw>?	M4nNTmlEPTB;MUCg{txO	NILkSGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
HOS	NYmybIdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkS0NVAh\|ryP	M3\tW\|czKGh?	NIS5SYdFVVOR	NXzwfXh4UUN3ME2xNEDPxE1?	Mm\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HPAF-II	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Hv[\|ExKM7:TR?=	MVO3NkBp	MmD2SG1UVw>?	MmTsTWM2OD1zMDFOwG0>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
Hs746.T	NXLwdJU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVGxNEDPxE1?	M2PHOlczKGh?	NUXJeZRHTE2VTx?=	MlPiTWM2OD1zMDFOwG0>	M37Z[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
HT	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEK5bVUyOCEQvF2=	MlnuO\|IhcA>?	M4LZ[mROW09?	Mn3VTWM2OD1zMDFOwG0>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
HT-3	MkTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;k[GUyOCEQvF2=	MWq3NkBp	NYnxSlZxTE2VTx?=	NXTGNGsyUUN3ME2xNEDPxE1?	MlHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
HuNS-1	NGfBe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVKxNEDPxE1?	Mn;ZO\|IhcA>?	MVvEUXNQ	M3nURWlEPTB;MUCg{txO	Mmi0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
IGROV1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmftNVAh\|ryP	MWS3NkBp	NVjmenF6TE2VTx?=	NEizfVRKSzVyPUGwJO69VQ>?	M{HFcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
J82	MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXuUFcyOCEQvF2=	M3WzbVczKGh?	MYXEUXNQ	M1;5UWlEPTB;MUCg{txO	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
JM1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2j4UVExKM7:TR?=	MoLwO\|IhcA>?	M{XDfGROW09?	NXL2V\|VYUUN3ME2xNEDPxE1?	NUDLeWxTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Kato III	NULCfVc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXexNEDPxE1?	MoPSO\|IhcA>?	M33z[mROW09?	MVLJR\|UxRTFyIN88US=>	M2HaVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
KHOS-240S	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1vLVFExKM7:TR?=	MYO3NkBp	NV63SpdWTE2VTx?=	NWTIXpNKUUN3ME2xNEDPxE1?	M1G2TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
KM-12	M{HiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfZcFIyOCEQvF2=	NHLMSoY4OiCq	MUPEUXNQ	M2K5eGlEPTB;MUCg{txO	M1\EXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
KPL-1	M1P1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;yNWwyOCEQvF2=	NHTWTnI4OiCq	MlW1SG1UVw>?	NVH3b4FwUUN3ME2xNEDPxE1?	NGjXNm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
KYSE-30	Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUWxNEDPxE1?	NHXMVWs4OiCq	MnnPSG1UVw>?	NYj5WpRiUUN3ME2xNEDPxE1?	MnHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
LNCaP	M3iw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fzPVExKM7:TR?=	M4PKWlczKGh?	M1:4WmROW09?	NIXUS\|hKSzVyPUGwJO69VQ>?	M17WXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
MCF-7	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYGxNEDPxE1?	MWe3NkBp	M4DKVWROW09?	MnXmTWM2OD1zMDFOwG0>	Mk\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MC-IXC	NXmxRohGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3:0WFExKM7:TR?=	NX3RcY1oPzJiaB?=	MU\EUXNQ	NFHPWWdKSzVyPUGwJO69VQ>?	NV\wPG1RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
MDA-MB-175 VII	M17ZXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjkR4FMOTBizszN	NEDTcI44OiCq	MVfEUXNQ	M2D0TmlEPTB;MUCg{txO	NFfmN2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
MDA-MB-468	NEPpWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPlNVAh\|ryP	NGLGTFg4OiCq	MYHEUXNQ	NHrCN\|VKSzVyPUGwJO69VQ>?	MkXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
MiaPaCa	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4P1ZlExKM7:TR?=	MnLBO\|IhcA>?	NVnxXmpWTE2VTx?=	MYTJR\|UxRTFyIN88US=>	Mof1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
Molt-4	NHuy[o1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF3CSIoyOCEQvF2=	NVi5[5BNPzJiaB?=	M4PHNWROW09?	NUL1Z3VIUUN3ME2xNEDPxE1?	NY\jfnRZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-ADR/RES	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV33TlVpOTBizszN	Ml[2O\|IhcA>?	NVLGW4NITE2VTx?=	NX3UUmpbUUN3ME2xNEDPxE1?	NIP3WW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H69	M4fVd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYixNEDPxE1?	NUOxUohnPzJiaB?=	NFTEe\|dFVVOR	MmfHTWM2OD1zMDFOwG0>	NHPRZ5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H82	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmO0NVAh\|ryP	M1XERlczKGh?	NUfSVYZxTE2VTx?=	M2nr[WlEPTB;MUCg{txO	NWjxc3VwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-N87	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUKxNEDPxE1?	Ml60O\|IhcA>?	MoDxSG1UVw>?	NILNdG5KSzVyPUGwJO69VQ>?	NVK4[FdqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H146	NUDQTFhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVf0[FlROTBizszN	M3LU[FczKGh?	M{DuS2ROW09?	NIrZUHRKSzVyPUGwJO69VQ>?	Mn\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H157	M3i4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnqU\|cyOCEQvF2=	MnrLO\|IhcA>?	M4fkUWROW09?	M3HQeGlEPTB;MUCg{txO	NU\QXJJLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H187	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{ftOFExKM7:TR?=	MXW3NkBp	NIHGZnhFVVOR	NV36c4pPUUN3ME2xNEDPxE1?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H209	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYOxNEDPxE1?	MWK3NkBp	MkPOSG1UVw>?	MXXJR\|UxRTFyIN88US=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H226	MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXSVII{OTBizszN	M2j3e\|czKGh?	M4\SZ2ROW09?	NHHX[2dKSzVyPUGwJO69VQ>?	MlHNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H292	NHrVXodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvrUGwyOCEQvF2=	NH\sfGQ4OiCq	NUD3VWYyTE2VTx?=	MmLSTWM2OD1zMDFOwG0>	NWnUOFY{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
NCI-H322	NIK4[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLtZ2IyOCEQvF2=	MX[3NkBp	NWDPdlhiTE2VTx?=	M1zk[mlEPTB;MUCg{txO	M3jvUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H358	NHnZXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVKxNEDPxE1?	Mly2O\|IhcA>?	NVz3V5ZWTE2VTx?=	M2npXmlEPTB;MUCg{txO	NEH1bYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H520	Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXj4bZRkOTBizszN	MYq3NkBp	M4LUSmROW09?	NFTvd\|VKSzVyPUGwJO69VQ>?	NEXJdms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H526	MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\tSWMyOCEQvF2=	NELVRWY4OiCq	MkDBSG1UVw>?	MVvJR\|UxRTFyIN88US=>	NFy3[mg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H630	NIrIcYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXKxNEDPxE1?	NWnGTW0zPzJiaB?=	NFPaT\|BFVVOR	MlXETWM2OD1zMDFOwG0>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H661	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7TNVAh\|ryP	NFPYTVA4OiCq	MnTWSG1UVw>?	NWTw[VRLUUN3ME2xNEDPxE1?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H716	M3Xo[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXocGcyOCEQvF2=	MVe3NkBp	Mon1SG1UVw>?	M4PPV2lEPTB;MUCg{txO	MnvUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
NCI-H1563	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfLe4EyOCEQvF2=	MkTzO\|IhcA>?	M2nyS2ROW09?	MWnJR\|UxRTFyIN88US=>	M2\QelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
NCI-H1792	NELERppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYWxNEDPxE1?	MoP5O\|IhcA>?	NHm5[JhFVVOR	MV;JR\|UxRTFyIN88US=>	NEfxcY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H2030	NXPhfFZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{T4[VExKM7:TR?=	M13OSlczKGh?	NXzhOY1ETE2VTx?=	NGXQclNKSzVyPUGwJO69VQ>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H2052	NELib\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\zWlExKM7:TR?=	NY\0eHdpPzJiaB?=	M4HyPWROW09?	M{XoV2lEPTB;MUCg{txO	NEXhXoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
NCI-H2122	NIjmN\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYqxNEDPxE1?	Mn[1O\|IhcA>?	NULHNVVRTE2VTx?=	M3TRc2lEPTB;MUCg{txO	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
NCI-H2228	NYDySnBmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfLc2YyOCEQvF2=	NHPI[VY4OiCq	M2LUTWROW09?	NW\MUJRCUUN3ME2xNEDPxE1?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
OE-19	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfSNmM2OTBizszN	M3e2T\|czKGh?	MnLySG1UVw>?	NH\6fpRKSzVyPUGwJO69VQ>?	NXLhTHJmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
OE-21	MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPEVlcyOCEQvF2=	M4PKc\|czKGh?	NVfSRnZiTE2VTx?=	NU\adZRkUUN3ME2xNEDPxE1?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
OE-33	Mk\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWKxNEDPxE1?	MYC3NkBp	NEjRNXNFVVOR	NGHj[4dKSzVyPUGwJO69VQ>?	NX;XeJp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
OVCAR-3	M2n5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGfhS\|kyOCEQvF2=	MV63NkBp	NWniPYloTE2VTx?=	NFm5U3ZKSzVyPUGwJO69VQ>?	M4DNeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
OVCAR-4	MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfQVJIzOTBizszN	MkfsO\|IhcA>?	M2W2e2ROW09?	M{LwUmlEPTB;MUCg{txO	MnPOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
OVCAR-5	Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MY[xNEDPxE1?	M13pdFczKGh?	NF71UpNFVVOR	MUjJR\|UxRTFyIN88US=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
P3HR-1	M{T1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEmwPXIyOCEQvF2=	MknlO\|IhcA>?	Mke3SG1UVw>?	NEXGfWhKSzVyPUGwJO69VQ>?	M{DJWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
PC-3	NIDHUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LjTlExKM7:TR?=	M1;NTVczKGh?	M2ntTmROW09?	NU[5OpFUUUN3ME2xNEDPxE1?	NWKwRnprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
Raji	M4P5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXKxNEDPxE1?	MoroO\|IhcA>?	MYTEUXNQ	MojZTWM2OD1zMDFOwG0>	M3fqdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
RD	NFqyPIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHWWHMyOCEQvF2=	NXT4N4NWPzJiaB?=	NVr0RY1iTE2VTx?=	NIjhZ5VKSzVyPUGwJO69VQ>?	M1rMZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
RD-ES	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvwSo0yOCEQvF2=	MXi3NkBp	MnqwSG1UVw>?	NX;yU\|ZGUUN3ME2xNEDPxE1?	NFnnTIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
RL	NXrrNoYxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vWVFExKM7:TR?=	M{fiblczKGh?	MoTFSG1UVw>?	MWfJR\|UxRTFyIN88US=>	NGLmcHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SaOS2	NG\y[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fXOVExKM7:TR?=	MmniO\|IhcA>?	NFrXPYtFVVOR	M2CzdGlEPTB;MUCg{txO	NVPYXYk5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SCC-9	M33zTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXixNEDPxE1?	M2LvZ\|czKGh?	NHzDSpVFVVOR	NEDzR4lKSzVyPUGwJO69VQ>?	M4m3N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SCC-12	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1uw[VExKM7:TR?=	NUC2WJBFPzJiaB?=	NGnnfXRFVVOR	MUfJR\|UxRTFyIN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SCC-13	MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1v0NFExKM7:TR?=	NWrFOXBmPzJiaB?=	NHvTSIJFVVOR	NHjLTI1KSzVyPUGwJO69VQ>?	Mli0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SCC-15	NFPLWYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGn0NJEyOCEQvF2=	M1XEeVczKGh?	NGnCeI9FVVOR	MXnJR\|UxRTFyIN88US=>	MlXQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SCC-25	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDyb\|hkOTBizszN	MlPPO\|IhcA>?	NGjwc49FVVOR	NX32OWMyUUN3ME2xNEDPxE1?	NHjwOFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SCLC-3	NUDDcXJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVixNEDPxE1?	NIDrXnM4OiCq	MVnEUXNQ	Mn7yTWM2OD1zMDFOwG0>	NEjCVGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SF-268	NEnrdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYixNEDPxE1?	MV:3NkBp	M1HidGROW09?	NVq5SFF5UUN3ME2xNEDPxE1?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SF-295	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfiRohvOTBizszN	NUK5S2xbPzJiaB?=	MYLEUXNQ	MWLJR\|UxRTFyIN88US=>	M3XRUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SJRH30	NG[4ToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\XUlExKM7:TR?=	MlLVO\|IhcA>?	MYPEUXNQ	NGixVGlKSzVyPUGwJO69VQ>?	M4\jW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-BR-3	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEnBRYwyOCEQvF2=	NFGwWI04OiCq	NV7NboZ6TE2VTx?=	NUnlU4xLUUN3ME2xNEDPxE1?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SK-LMS-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TuTVExKM7:TR?=	MkfvO\|IhcA>?	Ml\LSG1UVw>?	M3zkSmlEPTB;MUCg{txO	M1zERlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-N-DZ	M2TsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PUTFExKM7:TR?=	MXG3NkBp	MXLEUXNQ	MXXJR\|UxRTFyIN88US=>	NW\L[JBIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SK-N-F1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjkNVAh\|ryP	M3Swc\|czKGh?	NUHDSIVkTE2VTx?=	MWfJR\|UxRTFyIN88US=>	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SKOV-3	MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2roOlExKM7:TR?=	NYq2[3NoPzJiaB?=	NU[5[mVuTE2VTx?=	NVPHbZFzUUN3ME2xNEDPxE1?	M2jSeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SK-UT-1	NVP5fohoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTTSWN4OTBizszN	MUW3NkBp	MoTxSG1UVw>?	MnzyTWM2OD1zMDFOwG0>	MorvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SN12C	NV;4S3ZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{TTSlExKM7:TR?=	MYC3NkBp	NVXQVoc1TE2VTx?=	NYD0cYdUUUN3ME2xNEDPxE1?	M4rDNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SNB-19	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXexenRMOTBizszN	MVK3NkBp	MnWwSG1UVw>?	NIPiUoNKSzVyPUGwJO69VQ>?	MnS5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SNU-5	MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PHcVExKM7:TR?=	NGCzbWY4OiCq	MmSzSG1UVw>?	NVjzWIN6UUN3ME2xNEDPxE1?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SNU-16	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLNOpVFOTBizszN	NHqyNFM4OiCq	NXrZNJRwTE2VTx?=	MVHJR\|UxRTFyIN88US=>	NWTleZZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SNU-398	NEfuSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{O2W\|ExKM7:TR?=	NIrVVGY4OiCq	M1LHbmROW09?	NF24T5ZKSzVyPUGwJO69VQ>?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
SNU-449	NVTid2ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYWxNEDPxE1?	NGDTXFY4OiCq	NXXkWZRYTE2VTx?=	NUHIZ2FJUUN3ME2xNEDPxE1?	MmjpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
SR	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PmTlExKM7:TR?=	M3H3U\|czKGh?	NVz6e4lITE2VTx?=	MnXOTWM2OD1zMDFOwG0>	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
ST486	NXzuO403T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX6xNEDPxE1?	NYjQZ\|BXPzJiaB?=	M3;CVGROW09?	M17pZWlEPTB;MUCg{txO	NXLVVXlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
SW579	NULxeI9mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVuxNEDPxE1?	NXO1cVRGPzJiaB?=	MWDEUXNQ	M2XZW2lEPTB;MUCg{txO	M3Pic\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW684	NWOwUZAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYGxNEDPxE1?	NETXU5Y4OiCq	NUDLW3g2TE2VTx?=	NEL0O\|NKSzVyPUGwJO69VQ>?	M3uwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW-780	M4LNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn6wNVAh\|ryP	MYC3NkBp	NHyyc49FVVOR	NH;ieYVKSzVyPUGwJO69VQ>?	NFrZTpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
SW900	NFuyXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfkbGsyOCEQvF2=	NF71[2s4OiCq	NWDYcGFITE2VTx?=	NUH4RXp7UUN3ME2xNEDPxE1?	M3npRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW1088	NGjqdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4j6OVExKM7:TR?=	NYm5NpRkPzJiaB?=	NH7GcZZFVVOR	M2TRfWlEPTB;MUCg{txO	M3m3T\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW1463	M4fue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEn3bZUyOCEQvF2=	M4i0flczKGh?	NXq4W2pqTE2VTx?=	NHW2XmdKSzVyPUGwJO69VQ>?	M3nOU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
SW1990	NI[0RYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonFNVAh\|ryP	M2frdVczKGh?	MYjEUXNQ	M4TUSGlEPTB;MUCg{txO	MmDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
T47D	NETRO3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rPelExKM7:TR?=	MUK3NkBp	M1m1SGROW09?	NETkb\|FKSzVyPUGwJO69VQ>?	NWjLelhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
TE381.T	NX;QOZVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFSy[VQyOCEQvF2=	M33ue\|czKGh?	M2W0TmROW09?	Mn7mTWM2OD1zMDFOwG0>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzh2NECzPEc,OjN6NESwN\|g9N2F-
TK-10	NULFZ3lMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX[xNEDPxE1?	NGnWRmc4OiCq	NFznfXNFVVOR	MXrJR\|UxRTFyIN88US=>	MmTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
U2OS	Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7qNFcyOCEQvF2=	M2XIcFczKGh?	Mk\CSG1UVw>?	NXHNbm5yUUN3ME2xNEDPxE1?	MoTOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESwN\|goRjJ\|OES0NFM5RC:jPh?=
U251	M3nMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLmNVAh\|ryP	NVHX[mZNPzJiaB?=	NVfaOVBqTE2VTx?=	NH3ucVNKSzVyPUGwJO69VQ>?	NVXkO4Z[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQxOzhpPkKzPFQ1ODN6PD;hQi=>
UACC-812	NHPjPIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUixNEDPxE1?	MlzxO\|IhcA>?	MV;EUXNQ	NGS5fGFKSzVyPUGwJO69VQ>?	M{PTfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
YAPC	MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\Cc\|ExKM7:TR?=	M325UFczKGh?	MWDEUXNQ	MYTJR\|UxRTFyIN88US=>	NIrQPWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{i0OFA{QCd-MkO4OFQxOzh:L3G+
ZR-75-1	NFTnZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU[xNEDPxE1?	MkfJO\|IhcA>?	MVHEUXNQ	MVnJR\|UxRTFyIN88US=>	M{HvOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OES0NFM5Lz5{M{i0OFA{QDxxYU6=
A375	MofySpVv[3Srb36gZZN{[Xl?	MkTXNU4zKM7:TR?=	MnHtOEBp	NF7KbYJFVVOR	NGLGc2hKdmirYnn0bY9vKG:oIIDoc5NxcG:{eXzheIlwdiCxZjDNSWstKEWUSzygZY5lKFN4UB?=	MmT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|OEm0O\|EoRjJ{M{i5OFcyRC:jPh?=
YUSIT1	MkHUSpVv[3Srb36gZZN{[Xl?			NEHrUI1FVVOR	MVny[YR2[2WmIIPlcpNqfGm4aYT5JJdqfGhiSVO1NEA,KDBwNTFOwG0>	NGXBPYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkO4PVQ4OSd-MkKzPFk1PzF:L3G+
MeWo	M3jUSWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7			NXnKdmdOTE2VTx?=	MUfJR\|UxKD1iOUi3JI5O	NYDqelNqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNVg2OjRpPkK2NFE5PTJ2PD;hQi=>
WiDr	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			M1HpbGROW09?	MkTRTWM2OCB;IEe2JI5O	MmK4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMUi1NlQoRjJ4MEG4OVI1RC:jPh?=
Colo-205	MoS1SpVv[3Srb36gZZN{[Xl?	MYqxJO69VQ>?	NWPCOIhJPCCm	NV3jfJAzTE2VTx?=	MmLITY5lfWOnZDDhJIhq\2iueTDjc41x[XKjYnzlJINwdXCjY4Tpc44heGinbn;0fZBm	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN6MUG1Nkc,OjV\|OEGxOVI9N2F-
RBW-1	MW\GeY5kfGmxbjDhd5NigQ>?	MoXmNUDPxE1?		NVn6TGhOTE2VTx?=	NGOyeIFPdyC{ZXT1Z5Rqd25ib3[gUYVsKDFxMjDwbI9{eGixconsZZRqd25?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NU[5NEc,OjR6OEW2PVA9N2F-
RBO-1	NUCwb5R[TnWwY4Tpc44h[XO\|YYm=	MVKxJO69VQ>?		MVrEUXNQ	MnKyTY5pcWKrdHnvckBw\iCPZXugNU8zKHCqb4PwbI9zgWyjdHnvci=>	NFvYVYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi4OVY6OCd-MkS4PFU3QTB:L3G+
RBO-2	MWHGeY5kfGmxbjDhd5NigQ>?	NGrL[I4yKM7:TR?=		NFn6S5VFVVOR	NWC1b\|NKUW6qaXLpeIlwdiCxZjCgUYVsKDFxMjDwbI9{eGixconsZZRqd25?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NU[5NEc,OjR6OEW2PVA9N2F-
RBOW	NFz5UG5HfW6ldHnvckBie3OjeR?=	NGL2OGgyKM7:TR?=		NFn0dGdFVVOR	MkP5TY5pcWKrdHnvckBw\iBiTXXrJFEwOiCyaH;zdIhwenmuYYTpc44>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh6NU[5NEc,OjR6OEW2PVA9N2F-
M257	NWfnWIVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrPR3doOTByIH7N	M3HRb\|czKGh?		MoLRSI9meyCwb4SgbY5pcWKrdDDwdo9tcW[ncnH0bY9vKG:oIF2yOVch[2WubDDoZZJjd3W{aX7nJJdqdGRidInw[UBDWkGI	NYnMS21wRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVc1PDZpPkKzN\|E4PDR4PD;hQi=>
LCP	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TjeFExOCCwTR?=	MkPIO\|IhcA>?		NYfxboZ7UW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9vKG:oIFzDVEBk\WyuIHjhdoJwfXKrbnegRnJCTiCYNkCwVkBufXSjboTheIlwdg>?	MmO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MUe0OFYoRjJ\|M{G3OFQ3RC:jPh?=
WM266	Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfzNVAxKG6P	MWO3NkBp		MYrJcohq[mm2aX;uJI9nKHC{b3zp[oVz[XSrb36gc4YhX01{Nk[gZ4VtdCCqYYLic5VzcW6pIFLSRWYhXjZyMVSgcZV1[W62YYTpc44>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzN{S0Okc,OjN\|MUe0OFY9N2F-
M257	NUnNfod2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvFNVAxKG6P	NHf1WW44OiCq		MmDFSI9meyCwb4SgbY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIF2yOVch[2WubDDoZZJjd3W{aX7nJJdqdGRidInw[UBDWkGI	NYTsRmRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNVc1PDZpPkKzN\|E4PDR4PD;hQi=>
LCP	M3jw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zQeFExOCCwTR?=	Mme0O\|IhcA>?		NWKwTFlCUW6qaXLpeEBGWktzLUKgdIhwe3Cqb4L5cIF1cW:wIHnuJGxEWCClZXzsJIhiemKxdYLpcochSlKDRjDWOlAxWiCvdYThcpRifGmxbh?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNzN{S0Okc,OjN\|MUe0OFY9N2F-
WM266	NXO0U4wyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NE\2R5oyODBibl2=	M{XXbVczKGh?		MoDhTY5pcWKrdDDFVmsyNTJicHjvd5Bpd3K7bHH0bY9vKGmwIGfNNlY3KGOnbHygbIFz[m:3cnnu[{BDWkGIIG[2NFBFKG23dHHueIF1cW:w	NFmzN2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OxO\|Q1Pid-MkOzNVc1PDZ:L3G+
A375	MlvJRnJCTiClb33w[ZRqfGm4ZTDibY5lcW6pIHHzd4F6		MkLpNVUhdWmw		NYDPXI9RUUN3MDC9JFAvODB4IN88US=>	NHfabFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm2OVgxPCd-MkW5OlU5ODR:L3G+
A375	NXXwTpFPTnWwY4Tpc44h[XO\|YYm=		NFK1NZQ4OiCq		NFzmfWRKSzVyIE2gNE4xOTFizszN	MkjhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7NkW4NFQoRjJ3OU[1PFA1RC:jPh?=
A375	NEDz[4ZCWkGIIHPvcZBmfGm2aY\lJIJqdmSrbnegZZN{[Xl?		NX3renQ5OTVibXnu		M1vQSGlEPTBiPTCwMlAzPiEQvF2=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl4NUiwOEc,OjV7NkW4NFQ9N2F-
A375	M3ri[WNTSUZiY3;tdIV1cXSrdnWgZolv\GmwZzDhd5NigQ>?		NUX6NHp[OTVibXnu		NIPWVmNKSzVyIE2gNE4yPSEQvF2=	M3zDbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[1PFA1Lz5{NUm2OVgxPDxxYU6=
HCT116	NX\uVJY{TnWwY4Tpc44h[XO\|YYm=				M4X3WmlEPTBiPTC1Mlg5KM7:TR?=	M1uxUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OU[1PFA1Lz5{NUm2OVgxPDxxYU6=
A375	MXfGeY5kfGmxbjDhd5NigQ>?		MUCxJIg>		NFLTZYlKSzVyIE2gNE4xODFizszN	NVfZXIxQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFU3PzJpPkK3NFg2Pjd{PD;hQi=>
MIAPaCa2	MofpSpVv[3Srb36gZZN{[Xl?		NELDb3cyKGh?		MX7FR\|UxKD1iMD61Nlkh\|ryP	NWrSW\|dTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewPFU3PzJpPkK3NFg2Pjd{PD;hQi=>
A375	NILVSGNHfW6ldHnvckBie3OjeR?=				MYfJR\|UxKD1iMD6wNFQh\|ryP	M3HObFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[xPFI4Lz5{OUS2NVgzPzxxYU6=
SK-MEL-28	NV;MTnZPS3m2b4TvfIlkcXS7IHHzd4F6		NF;mcHI4OiCq		MVnJR\|UxKD1iMD6wOFMh\|ryP	MmrzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NkG4NlcoRjJ7NE[xPFI4RC:jPh?=
Sf9	NYHqPVdNTnWwY4Tpc44h[XO\|YYm=		NFztN5E3OCCvaX6=		MV;JR\|UxKD1iMD6wNFkh\|ryP	NYLwbHZwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O\|QyOzdpPkK3O\|c1OTN5PD;hQi=>
SK-MEL-28	M3T1dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NW[zWlF{PDhiaB?=		MVTHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDTT{1OTUxvMkigZ4VtdHNiaHHyZo9zcW6pIFLSRWYhXjZyMFWgcZV1[W62IH3lZZN2emWmIHHmeIVzKDR6IHjyd{Bz\XOjeoXybY4h[XO\|YYm=	NHXOTXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFE{Pyd-Mke3O\|QyOzd:L3G+
SK-MEL-28	NXjzd4hWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWi0PEBp		M1rsdmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yPEBk\WyuczDoZZJjd3KrbnegRnJCTiCYNkCwSUBufXSjboSgdJJmcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IHnydoFlcWG2aX;uJI9nKDFwMUOgb3cwdTJiVW[tcIlocHRiZn;yJFUhdWmwczDt[YF{fXKnZDDh[pRmeiB2ODDodpMhemW\|YYr1dolvKGG\|c3H5	MkG1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxN\|coRjJ5N{e0NVM4RC:jPh?=
SK-MEL-28	M{nZNWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NIfjfpE1QCCq		NYjLeHJOS3m2b4P0ZZRq[yCjY4Tpeol1gSCrbjDoeY1idiCVSz3NSWwuOjhiY3XscJMhcGG{Yn;ybY5oKEKUQV[gWlYxOEVibYX0ZY51KGG2IEGgZY5lKDNyIIXNJI1m[XO3cnXkJIFnfGW{IES4JIhzeyC{ZYPhfpVzcW5iYYPzZZk>	NH7qV2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFE{Pyd-Mke3O\|QyOzd:L3G+
DAOY	MnH1VJJqdWG{eTDzZ5Jm\W5iYYPzZZk>				NHfId4tyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiRFHPXUBk\Wyucx?=	NIW4cmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NIXhNW9RemmvYYL5JJNkemWnbjDhd5NigQ>?				NF;KUZhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	M3;1dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NU\PfVg6WHKrbXHyfUB{[3KnZX6gZZN{[Xl?				NEjMXoZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pMEK / pERK / ERK; PubMed: 31158244 PLoS One Cell lines as shown were treated with dabrafenib, over a dose range, for 1 hour. UT = untransfected. Expression and/or phosphorylation of the indicated proteins were assessed by immunoblot. p-S6 / p-AKT308 / p-AKT473; PubMed: 24735930 Mol Cancer Western blot analysis of phosphorylated proteins in MAPK and the PI3K-AKT pathway after 24 hours exposure to increasing concentrations of dabrafenib. β-catenin; PubMed: 29167314 Mol Cancer Ther HT-29 cells were treated with BRAF inhibitors Dabrafenib (2 μM), GDC-0879 (4 μM) or Vemurafenib (2 μM) for indicated times. The whole cell lysates were used for western blot with indicated antibodies.	31158244 24735930 29167314
Growth inhibition assay	IC50; PubMed: 24735930 Mol Cancer A panel of 23 BRAF(V600) mutant human melanoma cell lines was treated with serial dilutions (1-10,000 nM) of dabrafenib (A) for 72-120 hours to assess cell viability. The bars represent the average IC50 value of two or more independent experiments in duplicates and the error bars represent the SEM.	24735930

In vivo

Dabrafenib (orally administrated) inhibits the growth of B-RafV600E mutant melanoma (A375P) and colon cancer (Colo205) human tumor xenografts, growing subcutaneously in immuno-compromised mice. ^[1]

Protocol

References

Solubility (25°C)

In vitro	DMSO	30 mg/mL (57.74 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+45% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Dabrafenib (GSK2118436) SDF

Molecular Weight	519.56
Formula	C₂₃H₂₀F₃N₅O₂S₂
CAS No.	1195765-45-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	GSK2118436A
Smiles	CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04961619	Not yet recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma	Novartis Pharmaceuticals\|Novartis	October 20 2021	--
NCT04547946	Not yet recruiting	Drug: dabrafenib + trametinib	Malignant Melanoma	Novartis Pharmaceuticals\|Novartis	September 30 2021	--
NCT04775095	Recruiting	--	Non Small Cell Lung Cancer\|BRAF V600 Mutation	Intergroupe Francophone de Cancerologie Thoracique\|Novartis	March 8 2021	--
NCT04666272	Recruiting	Drug: dabrafenib\|Drug: trametinib	Melanoma	Novartis Pharmaceuticals\|Novartis	December 31 2020	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Pan Raf Inhibitor

AZ 628 : Pan-Raf inhibitor, BRAF, IC50=105 nM; BRAFV600E, IC50=34 nM; c-Raf-1, IC50=29 nM.
FDA-approved Raf Inhibitor

Sorafenib Tosylate : Approved by FDA for advanced renal cancer。
Newest Raf Inhibitor

TAK-632 ^New : Potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf, respectively, showing less or no inhibition against other tested kinases.

Related Raf Products

LY3009120 ^New

LY03009120 (DP-4978) is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. LY03009120 induces autophagy. Phase 1.
Ravoxertinib (GDC-0994) ^New

Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Ulixertinib (BVD-523) ^New

Ulixertinib (BVD-523, VRT752271) is a potent and reversible ERK1/ERK2 inhibitor with IC50 of <0.3 nM for ERK2. Phase 1.
Vemurafenib (PLX4032)

Vemurafenib (PLX4032, RG7204, RO5185426) is a novel and potent inhibitor of B-Raf^V600E with IC50 of 31 nM in cell-free assay. 10-fold selective for B-Raf^V600E over wild-type B-Raf in enzymatic assays and the cellular selectivity can exceed 100-fold. Vemurafenib (PLX4032, RG7204) induces autophagy.

Features:A novel and potent inhibitor of the B-RAF^V600E oncoprotein.
Sorafenib (BAY 43-9006)

Sorafenib (BAY 43-9006, NSC-724772) is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
Sorafenib (BAY 43-9006) tosylate

Sorafenib (BAY 43-9006) tosylate is a multikinase inhibitor of Raf-1 and B-Raf with IC50 of 6 nM and 22 nM in cell-free assays, respectively. Sorafenib Tosylate inhibits VEGFR-2, VEGFR-3, PDGFR-β, Flt-3 and c-KIT with IC50 of 90 nM, 20 nM, 57 nM, 59 nM and 68 nM, respectively. Sorafenib Tosylate induces autophagy and apoptosis and activates ferroptosis with anti-tumor activity.
PLX-4720

PLX4720 is a potent and selective inhibitor of B-Raf^V600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
TAK-632

TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
GDC-0879

GDC-0879 (AR-00341677) is a novel, potent, and selective B-Raf inhibitor with IC50 of 0.13 nM in A375 and Colo205 cells with activity against c-Raf as well; no inhibition known to other protein kinases.
GW5074

GW5074 is a potent and selective c-Raf inhibitor with IC50 of 9 nM, no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms is noted. GW5074 inhibits LK-induced apoptosis.

Choose Your Country or Region

By Signaling Pathways

By product type

Dabrafenib (GSK2118436)